^
Association details:
| Biomarker: | MDM2 amplification + TWIST1 amplification |
|---|---|
| Cancer: | Sarcoma |
| Drug: | milademetan (RAIN-32) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).
Published date:
05/25/2023
Excerpt:
...we found that anti-tumor activity correlated with amplified TWIST1 (p-value = 0.028)…amplified TWIST1 could be associated with the anti-tumor activity of milademetan in patients with amplified MDM2 intimal sarcoma.
DOI:
10.1200/JCO.2023.41.16_suppl.11544
